The antimalarial drug hydroxychloroquine is indicated for all patients with SLE regardless of disease severity because it decreases disease flares and decreases mortality (1); however, hydroxychloroquine is not used in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency because it can cause hemolysis.